PDS Biotechnology Corporation (PDSB)
| Market Cap | 49.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.36M |
| Shares Out | 55.82M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 632,135 |
| Open | 0.900 |
| Previous Close | 0.894 |
| Day's Range | 0.860 - 0.940 |
| 52-Week Range | 0.507 - 1.550 |
| Beta | 1.56 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+744.12%) |
| Earnings Date | Aug 12, 2026 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 744.12% from the latest price.
News
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
PDS Biotechnology Earnings Call Transcript: Q1 2026
Clinical programs advanced with protocol amendments expected to accelerate timelines and reduce costs. Net loss narrowed year-over-year, and new patents extend exclusivity into the 2040s. Additional data from colorectal cancer trials anticipated by year-end.
PDS Biotechnology Earnings release: Q1 2026
PDS Biotechnology released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
PDS Biotechnology Quarterly report: Q1 2026
PDS Biotechnology has published its Q1 2026 quarterly earnings report on May 13, 2026.
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy co...
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotechnology Registration statement: Registration filing
PDS Biotechnology filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
PDS Biotechnology Slides: Corporate presentation
PDS Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC
PDS Biotechnology (PDSB) announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the Mar...
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%
PDS Biotechnology Earnings Call Transcript: Q4 2025
Clinical and financial progress included a reduced net loss, lower operating expenses, and key advances in HPV-16 cancer trials. FDA-cleared protocol amendments are expected to accelerate regulatory timelines, while new patents extend market protection into the 2040s.
PDS Biotechnology Annual report: Q4 2025
PDS Biotechnology has published its Q4 2025 annual report on March 30, 2026.
PDS Biotechnology Earnings release: Q4 2025
PDS Biotechnology released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Ne...
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer
PDS Biotechnology announces new U.S. patent covering tech underlying PDS0101
PDS Biotechnology (PDSB) announced that the U.S. Patent Office has issued a Notice of Allowance for the Company’s lead asset, PDS0101. “This patent reinforces the value of our proprietary Versamune…
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years Patent Enhances IP Estate for Lead Asset; Combined with Anticipated B...
PDS Biotechnology announces FDA alignment on use of PFS as primary endpoint
PDS Biotechnology (PDSB) announced that the Company has submitted a protocol amendment to the U.S. FDA for its Phase 3 VERSATILE-003 clinical trial. The proposed amendment to the VERSATILE-003 Phase…
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEW...
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINC...
PDS Biotechnology announces request for Type C Meeting with FDA for PDS0101
PDS Biotechnology (PDSB) announced that its request for a Type C Meeting with the FDA has been accepted by the agency, and the meeting has been scheduled to occur this…